News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Investor Conference Call - Clinical Trial Results
Pharmaxis Ltd expects to complete its analysis and announce the results of its second international Phase III clinical trial of Bronchitol in patients with cystic fibrosis prior to the end of today, 22 June 2010. The announcement will have the effect of lifting the current trading halt over the company's shares.
Pharmaxis CEO
The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that the company's Chief Executive Officer Dr Alan Robertson has undergone a medical procedure. Dr Robertson is expected to make a full recovery but will be absent from the office for the next few weeks.
Read full media release - pdf
Pharmaxis announces sustained benefit in cystic fibrosis following long term bronchitol treatment
Pharmaxis today announced significant headline results for the final stage of its international Phase III trial of Bronchitol (inhaled mannitol) in people with cystic fibrosis.
Read full media release - pdf